Document:

EX-10.7

 Exhibit 10.7 
 Summary of BSA Plan 
 Similar to share options, non-employee warrants, or BSAs,
entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. In addition to any
exercise price payable by a holder upon the exercise of any non-employee warrant, non-employee warrants need to be subscribed for at a price at least equal to five percent (5%) of the exercise price of the underlying ordinary shares, which
subscription price is meant to reflect at least the fair market value of the applicable warrants on the date of grant. There is no legal limitation to the size of the non-employee warrant pool. 

Administration. Pursuant to delegations granted at our annual shareholders’ meeting our board of directors determines the recipients,
dates of grant and exercise price of non-employee warrants, the number of non-employee warrants to be granted and the terms and conditions of the non-employee warrants, including the period of their exercisability and their vesting schedule. The
board of directors has the authority to extend the post-termination exercise period of non-employee warrants after the end of the term of office. 
 Non-Employee Warrants. Our non-employee warrants are generally granted subject to a vesting schedule providing for either: (1) 1/24th at the expiration of each month following
the date of grant, subject to continued service, if granted to the advisory board members, or (2) 1/3 to be vested on the date of grant and 1/3 to vest each year following the date of appointment of the relevant director, if granted to the
independent directors, in both cases subject to continued service. The term of non-employee warrants is ten years from the date of grant or, in the case of death or disability of the beneficiary during such ten-year period, six months from the death
or disability of the beneficiary. Unless a longer period is specified in the notice of grant or otherwise resolved by the board of directors, a non-employee warrant shall remain exercisable for one month following a beneficiary’s termination of
continuous status with the Company. 
 Non-employee warrants may be transferred to any person and may be exercised by their holder at any time
subject to vesting. 
 Change in Control. Most of our non-employee warrants provide that in the event of a change in
control, as defined in the relevant grant documents, unvested warrants will automatically vest in full. 
 Initial Public
Offering. Certain non-employee warrants granted by us will become immediately exercisable upon completion of our initial public offering.EX-10.8

 Exhibit 10.8 
 Summary of BSPCE Plan 
 Similar to share options, employee warrants, or BSPCEs,
entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. Employee warrants
may only be issued by growth companies meeting certain criteria. There is no legal limitation to the size of the employee warrant pool under French law. 
 Administration. Pursuant to delegations granted at our annual shareholders’ meeting our board of directors determines the recipients, dates of grant and exercise price of employee
warrants, the number of employee warrants to be granted and the terms and conditions of the employee warrants, including the period of their exercisability and their vesting schedule. The board of directors has the authority to extend the
post-termination exercise period of employee warrants after the termination of the employment agreement. 
 Employee
Warrants. Our employee warrants granted prior to November 2010 were generally granted subject to a three-year vesting schedule under which one-third (1/3) of the employee warrants vest upon the first anniversary of grant and
1/12th at the expiration of each quarter thereafter, subject to continued service. Our employee warrants granted since November 2010 were generally granted subject to a four-year vesting schedule under which one-fourth (1/4) of the employee
warrants vest upon the first anniversary of grant and 1/16th at the expiration of each quarter thereafter, subject to continued service. In each case, any warrant which is not exercised before the tenth anniversary of the date of grant will
automatically lapse. The term of each employee warrant is ten years from the date of grant or, in the case of death or disability of the beneficiary during such ten-year period, six months from the death or disability of the beneficiary in
accordance with French law. Unless a longer period is specified in the notice of grant or otherwise resolved by the board of directors, an employee warrant shall remain exercisable for one month following a beneficiary’s termination of
continuous status with the Company. 
 Employee warrants are not transferable and may not be sold, pledged, assigned, hypothecated, transferred
or disposed of in any manner other than by will or by laws of descent or distribution and may be exercised, during the lifetime of the beneficiary, only by the beneficiary. 
 Change in Control. Employee warrants granted prior to March 2011 provide that in the event of a change in control, as defined in the relevant grant documents, occurring after the
first anniversary of the date of grant, unvested warrants will automatically vest in full. Employee warrants granted since March 2011, other than the employee warrants vesting upon completion of this offering as described below, provide that
unvested warrants will only accelerate in case of a change in control at any time (whether prior to or after the first anniversary of grant) if the acquirer or the successor corporation does not agree to assume or substitute equivalent rights for
the outstanding employee warrants. 
 Initial Public Offering. The employee warrants granted to the three founders of the
Company in October 2012 for an aggregate of 644,224 ordinary shares will vest in full upon completion of our initial public offering provided that the offering is completed on or before October 31, 2013.EX-10.10

 Exhibit 10.10 
 CRITEO 
 WARRANT AGREEMENT 

[Name and Address of the recipient] 
 hereinafter referred to as the “Beneficiary” 
 On [.], the board of directors of
CRITEO S.A. (the “Company”), using the delegation of competence granted to it by the combined ordinary and extraordinary shareholders meeting held on [.], issued and granted to the benefit of the Beneficiary a total of [.] warrants
(the “Warrants”) under the terms and conditions set forth in this agreement: 
  

			
	Date of Grant:	  	[.]
		
	Subscription Price of the Warrants:	  	[.]
		  	(i.e., EUR [.] per Warrant)
		
	 Maximum number of ordinary shares to be subscribed upon exercise of the Warrants:

 
	  	 [.]
 (i.e., 1 per
Warrant)

		
	Exercise price per share:	  	EUR [.]
		
	Term/Expiration date of the Warrants:	  	[.]

 [The shares issued as a result of the exercise of a Warrant shall be held in the nominative form and shall not be sold
prior to the third anniversary of the Date of Grant of the relevant Warrant, except in the context of an Operation (as defined below). This prohibition of sale will be mentioned in the individual shareholder’s account of the Beneficiary.]

 Article 1 - Validity of the Warrants 
 The Warrants will be validly issued as from the date of their subscription by the Beneficiary subject to the condition precedent that the Beneficiary executes and returns to the Company the following
document, duly signed, and makes the following payment on or before [.]: 
  

	•	 	 the subscription form of the Warrants in the form attached as exhibit 1 hereto accompanied by the payment of the Subscription Price of the Warrants.

 The Warrants shall be fully paid up, at subscription, for a total price of EUR [.], in cash and/or by way of offset against
receivables in accordance with applicable French law. 

  
 1 

 Article 2 - Exercise of the Warrants 

 

	2.1.	Vesting period 

 The Warrants may be
exercised according to the following vesting agenda: 
  

	 	•	 	 [.] Warrants may be exercised as from [.]; 

  

	 	•	 	 [.] Warrants may be exercised as from [.]; and 

 

	 	•	 	 [.] Warrants may be exercised as from [.]. 

 Any Warrants not exercised on or before [.] shall be automatically void. 
 As an exception to the
above, in the event of the signature of a merger agreement by way of absorption of the Company by another Company, or in the event of the transfer by one or several shareholders of the Company to one or several third parties, acting on their own or
jointly, of a number of shares entailing the transfer of the control of the Company (in the meaning of article L. 233-3 of the French commercial code) to this or these third parties (hereinafter referred to as an « Operation »),
the exercise rights of the Warrants shall be accelerated in such a way that the Warrants holder can exercise, in addition to the number of shares which he has the right to purchase upon exercise of his Warrants already exercisable, a number of
ordinary shares corresponding to 100% of his Warrants not exercisable at the date of the completion of the said Operation. 
 However, unless
otherwise decided by the board of directors according to the events below, the exercisable Warrants will have to be exercised by their holder or beneficiaries, failing which they will be deemed to be null and void: 

 

	 	a)	within one month following the termination, on his own initiative or at the request of the Company, of the holder’s term of office as [title] of the Company, or

  

	 	b)	at the latest immediately prior to the completion of the above mentioned Operation, it being specified that the Company will have to inform the holder of Warrants of
the completion of any Operation of which he might not be aware at least fifteen (15) days in advance, or 

  

	 	c)	within six (6) months following the occurrence of the death or incapacity of the Warrants holder, 

it being specified that, on the one hand, the Warrants which would not be exercisable at the date of occurrence of one of the events listed under
paragraph (a) to (c) above will automatically lapse and that, on the other hand, the above mentioned delays shall not result in an extension of the validity of the Warrants beyond the above ten-year (10) period. 

 

	2.2.	Method of Exercise  

 The Warrants are
exercisable by delivery of an exercise notice, in the form attached hereto under exhibit 3 (the “Exercise Notice”), comprising a share subscription form (bulletin de souscription) which shall state the Beneficiary’s
election to exercise all or parts of the Warrants and the number of shares in respect of which the Warrants are being exercised (the “Exercised Shares”). The Exercise Notice shall be signed by the Beneficiary and shall be delivered
in person or by certified mail to the Company or its designated representative or by facsimile message to be immediately confirmed by certified mail to the Company. The Exercise Notice shall be accompanied by the payment of the aggregate exercise
price of all Exercised Shares. If the subscription price of the shares is paid by wire transfer, the subscription price of the shares will have to be paid on the Company’s bank account at the latest within ten (10) calendar days following
the receipt by the Company of the Exercise Notice. The Warrants shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the proof of payment of such aggregate exercise price. 

  
 2 

 Upon exercise of the Warrants, the shares issued to the Beneficiary shall be assimilated with all other
ordinary shares of the Company and shall be entitled to dividend for the fiscal year during which the Exercised Shares are subscribed and issued. 
  

	2.3.	Payment of the Exercised Shares 

 Payment
of the aggregate exercise price of the Exercised Shares shall be made, at the election of the Beneficiary, by: 
  

	 	(1)	bank wire transfer; or 

  

	 	(2)	check; or 

  

	 	(3)	offset against receivables in accordance with applicable French law; or 

 

	 	(4)	any combination of the foregoing methods of payment. 

 Article 3 - Other terms of the Warrants 
 In the event of a reduction in share
capital of the Company due to losses by way of reduction of the number of outstanding shares of the Company, the right of the holder of the Warrants as regards the number of shares to be issued upon exercise of the Warrants shall be reduced
accordingly, as if the Warrants holder had been a shareholder of the Company as from the date of issuance of the Warrants. 
 In the event of a
reduction in share capital of the Company due to losses by way of reduction of the par value of the Company’s shares, the subscription price of the shares issued upon exercise of the Warrants shall not change, the issue premium being increased
by the amount of the reduction of the par value. 
 In the event of a reduction in share capital of the Company not related to losses by way of
reduction of the par value of the shares, the subscription price of the shares issued upon exercise of the Warrants shall be reduced accordingly. 
 In the event of a reduction in share capital of the Company not related to losses by way of reduction of the number of shares, the holder of the Warrants, if he exercises the Warrants, shall be entitled
to request the repurchase of his shares under the same conditions as if he had been a shareholder of the Company as at the date of the repurchase by the Company of its own shares. 
 In case of rights issue (in which all shareholders are offered to participate prorata their respective equity stake), the Company will take either or several of the following decisions to preserve the
rights of the holder of the Warrants, in accordance with the provisions of article L. 228-99 of the French commercial code: 
 1. either
permit the holder of the Warrants to exercise it immediately to enable the Beneficiary to participate in the rights issue, which will not alter or limit the rights of the Beneficiary to exercise the Warrants under Section 2.1 of this Warrant
Agreement; or 
 2. take any measures which will allow the Beneficiary, should he exercises the Warrants subsequently, to irrevocably subscribe
at that time its prorata share of the new issue or obtain a free allotment, or receive cash or goods similar to those distributed in the rights issue, in the same quantities or proportions and under the same conditions as if the Beneficiary already
exercised the Warrants and had thus been a shareholder of the Company at the time when those operations took place, or 
 3. adjust the
conditions of subscription initially fixed in order to take account of the impact of the rights issue. In that case, such adjustment will be carried out by applying the method provided for in article R. 228-91 of French code of commerce, it
being specified that the value of the preferential subscription right as well as the value of the share before detachment of the 

  
 3 

 
subscription right shall be determined, if need be, by the board of directors on the basis of the subscription, exchange or sale price per share retained at the time of the last operation
occurred on the Company’s share capital (share capital increase, contribution in kind, sale of shares, etc.) during the six (6) month-period preceding the said meeting of the board of directors, or, if no such operation has been carried
out during the said period, on the basis of any other financial parameter that appears relevant to the board of directors (and which will be confirmed by the Company’s auditor). 
 The Company is authorized, without requesting the specific consent of the holder of the Warrants, to modify its corporate form and its corporate purpose. 

It is reminded that, in compliance with the provisions of article L. 228-98 of the French commercial code, the Company cannot amend the rules regarding
profit allocation, amortize the share capital and create and issue preferred shares entailing any such modification or amortization without requesting the specific consent of the holder of the Warrants. 

Article 4 - Governing Law 
 This
agreement is governed by the laws of the Republic of France. 
 Any claim or dispute arising under this agreement shall be subject to the
exclusive jurisdiction of the court competent for the place of the registered office of the Company. 
 Made on [.], in two (2) original
copies. 
  

					
	[.]	 	CRITEO
			
		 	By:	 	Benoît Fouilland
		 	Chief Financial Officer (CFO)

  
 4 

 EXHIBIT 1 
 SUBSCRIPTION FORM OF THE WARRANTS 

  
 5 

 CRITEO 
 French société anonyme with a share capital of EUR [.] 

Registered office: 32 rue Blanche, 75009 Paris 
 484 786 249 R.C.S. PARIS 
  

 

SUBSCRIPTION FORM 

Amount and terms of the issuance of the Warrants 
 Issuance at a total price of EUR [.] of [.] warrants (hereafter the “Warrants”), giving the right to subscribe a maximum number of [.] ordinary shares, at a fixed price of EUR [.]
each (issue premium included), to be fully paid up in cash or by way of offset against receivables and the subscription of which has been reserved to the subscriber. 
 The issuance has been decided by the board of directors of Criteo on [.], pursuant to the authorization granted to it by the shareholders’ meeting of [.]. 

The terms and conditions of the Warrants are described in the warrant agreement executed by the subscriber and Criteo on [.]. 

The subscription period is opened from [.] to [.] included. 
 The amount of the subscription shall be addressed to the registered office of the Company or transferred on the bank account opened in the name of the Company with Bank [.], Bank Code: [.], Desk Code:
[.], Account: [.], Cle RIB: [.], IBAN International Bank Account Number [.] (the “Bank Account”). 

—ooOoo— 
 The
undersigned: 
 [.], residing [.], 

acknowledging the terms and conditions of the Warrants, 
 hereby subscribe the Warrants and pay the amount of my subscription, [i.e. EUR [.], by bank transfer to the Bank Account/EUR [.] partially by way of offset with due and payable receivables held against
the Company, amounting to a total of EUR [.] and corresponding to the directors fees owed to me pursuant to the resolution voted by Criteo’s board of directors on [.].] 

 

	
	Made in
	On
	In two copies
	
	  

	[.]

  
 1 

 EXHIBIT 2 

EXERCISE NOTICE OF THE WARRANTS 
 (Share subscription form) 
 CRITEO 
 32, rue Blanche 
 75009 Paris 

					
	France	 		  	[                    ], [    ]

 Attention:
[                    ] 
 [.], residing [.],

 holder of [.] Warrants, each giving right to subscribe for an ordinary share of Criteo (the “Company”) issued pursuant to
the resolution of the board of directors of the Company held on [.], 
 having examined the terms and conditions of the Warrants, 

hereby 
 exercise
[    —    ] Warrants 
 and 

subscribe consequently for [    —    ] ordinary shares
of the Company, for a subscription price per share of EUR [.] share premium included, 
 pays, for this subscription, the total amount of
EUR [    —    ], corresponding to the aggregate of the nominal value and the share premium of the above mentioned ordinary shares, 

by wire transfer to the Company’s bank account opened at [.], Bank Code: [.], Desk Code: [.], Account: [.], Cle RIB: [.], IBAN International Bank
Account Number [.] (the “Bank Account”). 
  

	
	Made in
	On
	In two copies
	
	  

	[.]
	

  
 -1-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]